Skip to Main Content

Tag: James Polli

Talent Competition Highlights Student Innovation in Regulatory Science (Featured Image)

Talent Competition Highlights Student Innovation in Regulatory Science

February 3, 2017

First-ever undergraduate competitor takes the gold for project to develop a universal labeling system for hazardous drugs.

Read More
SOP Talent Competition Brings Student Innovation to the Forefront

SOP Talent Competition Brings Student Innovation to the Forefront

February 19, 2016

Fourth annual M-CERSI “America’s Got Regulatory Science Talent” competition awards third-year student pharmacists first prize for novel solution to improve FDA’s post-marketing surveillance program.

Read More
School of Pharmacy Sees Unparalleled Growth in Research Funding

School of Pharmacy Sees Unparalleled Growth in Research Funding

December 7, 2015

New grants and contracts from a multitude of non-profit and government organizations, as well as the private sector, help the School of Pharmacy achieve the highest funding increase among all professional and graduate schools at the University of Maryland, Baltimore.

Read More
Standing Left to Right: James Polli, PhD; Janet Woodcock, MD; and Natalie Eddington, PhD, FCP, FAAPS

CERSI Symposium Highlights Use of Biomarkers in Drug Development

August 28, 2015

More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.

Read More
James Polli, PhD, and Tricia Ting, MD

UMB Conducts First-of-a-Kind Study on Bioequivalency of Anti-Epileptic Drug

August 14, 2015

Collaborative study helps validate effectiveness of FDA’s bioequivalence standard, showing no significant differences between major brand name and generic medication used to treat patients with epilepsy.

Read More
James Polli, PhD

SOP’s Polli Testifies for GDUFA Renewal at National Public Meeting

August 6, 2015

Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).

Read More
Sarah Michel, PhD, an associate professor in PSC, will lead the study, which includes an 18-month clinical trial with 48 healthy volunteers and research on the blood samples collected from the volunteers.

SOP Faculty Receive $1.5 Million from the FDA to Study Iron Medications

February 24, 2015

Interdisciplinary group will research the effectiveness of brand versus generic iron medications used to treat anemia in kidney disease patients

Read More